Trial
NCT00784524
Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Breast Cancer
Intervention
allogeneic large multivalent immunogen breast cancer vaccine
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-06